- Home
- LXRX vs BCYC Comparison
LXRX vs BCYC Comparison
Compare LXRX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | BCYC |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.5M | 438.4M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LXRX | BCYC |
|---|---|---|
| Price | $1.31 | $7.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $3.23 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 1.4M | 303.3K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,864,000.00 | $28,339,000.00 |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1255.21 | N/A |
| 52 Week Low | $0.28 | $6.03 |
| 52 Week High | $1.66 | $21.21 |
Technical Indicators
Market Signals| Indicator | LXRX | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 55.07 |
| Support Level | $1.29 | $7.03 |
| Resistance Level | $1.48 | $7.65 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 10.53 | 73.86 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.